SANTA CRUZ BIOTECHNOLOGY, INC.

C1QDC2 (A-13): sc-241306

BACKGROUND

C1QDC2, also known as FAM132A, is a 302 amino acid secreted protein that belongs to the FAM132 family. The gene encoding C1QDC2 maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Eudy, J.D., et al. 1998. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science 280: 1753-1757.
2. Tayebi, N., et al. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73: 313-321.
3. Plasilova, M., et al. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. Eur. J. Hum. Genet. 12: 365-371.
4. Betarbet, R., et al. 2008. Fas-associated factor 1 and Parkinson's disease. Neurobiol. Dis. 31: 309-315.
5. Holliday, E.G., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. Am. J. Psychiatry 166: 206-215.
6. Balcárková, J., et al. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. Cancer Genet. Cytogenet. 192: 68-72.
7. Yokoi, T., et al. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: FAM132A (human) mapping to 1p36.33; Fam132a (mouse) mapping to 4 E2.

SOURCE

C1QDC2 (A-13) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of C1QDC2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-241306 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

C1QDC2 (A-13) is recommended for detection of C1QDC2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

C1QDC2 (A-13) is also recommended for detection of C1QDC2 in additional species, including equine.

Suitable for use as control antibody for C1QDC2 siRNA (h): sc-78801, C1QDC2 siRNA (m): sc-141843, C1QDC2 shRNA Plasmid (h): sc-78801-SH, C1QDC2 shRNA Plasmid (m): sc-141843-SH, C1QDC2 shRNA (h) Lentiviral Particles: sc-78801-V and C1QDC2 shRNA (m) Lentiviral Particles: sc-141843-V.

Molecular Weight of C1QDC2: 32 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.